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1. Introduction 
Acute myeloid leukemia (AML) comprises approximately 25% of all leukemias in adults in 
the western world. It is a clonal disorder caused by uncontrolled proliferation and 
accumulation of myeloid progenitor cells in the bone marrow with impaired differentiation, 
leading ultimately to hematopoietic failure.  
Myelodysplastic syndrome (MDS) is characterized by persistent pancytopenia, dysplastic 
hematopoesis in bone marrow, increase in blast cell number and high risk of progression to 
AML. MDS is a disease of elderly, which makes treatment difficult (Estey 2008). The median 
age of AML patients is also high and is estimated to be 66 to 70 years. Standard therapeutic 
strategies in MDS and AML depend on various factors, of which age, comorbidities and 
performance status are most important. Treatment modalities vary from the best supportive 
care through low dose chemotherapy to intensive dose chemotherapy and allogeneic bone 
marrow transplantation (Robak T, Wierzbowska A 2009). Untreated MDS and AML carry 
extremely poor prognosis with high mortality. The search for new drugs in AML and MDS is 
stimulated by the significant progress in the understanding of the biology of both diseases.  
Abnormal myeloid cells usually carry chromosomal anomalies, including translocations, 
deletions, and allelic loss. Typical cytogenetic changes seen in AML are balanced 
translocations such as t(8,21), t(15,17) which result in formation of a fusion gene. MDS is 
characterized by deletions of fragments or whole chromosomes hence loss of genetic 
information. DNA methylation dysregulation is one of the postulated mechanisms of 
leukemia development and progression. Hypermethylation of DNA generally results in a 
decreased expression of tumor suppressor genes and defective cell cycle control and is a 
hallmark of MDS and AML. Epigenetic changes augment genetic alterations occurring in 
cancer cells and promote tumor progression. Several sequential events in the genom are 
required to create a leukemic clone. Defects of DNA repair are the key mechanism of 
development and progression of myeloid leukemias. Most of the AML cases originate de 
novo, but around 10 to 20% of patients have previous exposure to myelotoxic substances. 
Preceding anticancer treatment or exposure to chemical toxins may result in severe damage 
to DNA and in case of defective DNA repair mechanisms lead to secondary AML. DNA 
repair mechanisms may influence not only the risk of leukemia development, but also its 
refractoriness to treatment.  
Several major pathways of DNA repair exist: Homologous Recombination (HR), Non 
Homologous End Joining (NHEJ), Base Excision Repair (BER), Nucleotide Excision Repair 
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(NER), Mismatch Repair (MMR), Translesion DNA synthesis (TLS) (D’Andrea 2010, 
Shrivastav, de Haro et al 2008). HR and NHEJ are responsible for repair of DNA double 
strand breaks (DSB), caused mainly by ionizing radiation, free radicals, and chemical toxins 
including cytostatics. DSBs comprise DNA lesions most detrimental for cell survival. The 
other DNA repair mechanisms deal with single strand breaks and the presence of improper 
base or alkyl adducts in the DNA. A complementary strand is used as the repair template. 
Different DNA repair processes overlap in their function and usually one problem can be 
repaired in 2 different ways. In normal cells all of DNA repair pathways are active and 
balanced. In the case of irreversible DNA damage, cells are directed to apoptosis. When the 
damage is moderate and repair processes inadequate the cells accumulate dangerous 
mutations and genomic instability occurs. This is the first step of neoplastic transformation. 
The defective function of one of the DNA repair pathways often results in overexpression of 
the other one. Increased processes of DNA repair may lead to resistance to cytostatics and 
radiotherapy (Pallis, Karamouzis 2010). The role of DNA damage and repair processes in 
pathogenesis and treatment of cancer was first noted in patients with inherited syndromes 
with defective DNA repair mechanisms such as Fanconi anemia. Much information comes 
also from neoplastic disorders induced by factors known to damage DNA, such as ionizing 
radiation or cytostatic therapy.  
2. Secondary AML and MDS  
Secondary AML and MDS are most common therapy related neoplasms. Two main types of 
treatment-related AML exist depending on type of cytostatics administered. Secondary 
leukemia due to topoisomerase II inhibitors such as podophilotoxins and antracycline 
antibiotics, used in variety of solid tumors, occurs usually after short period of time (1 year) 
following chemotherapy. Characteristic features include chromosome 11q23 anomalies, total 
or partial deletion of chromosome 7 and certain balanced translocations such as t (8,21) or 
t(15,17). The mechanism of development of that type of treatment related AML is not clearly 
understood, but defects in DSB repair are thought to be a key mechanism. Antracycline 
antibiotics intercalate into DNA and stabilize DNA-topoisomerase II complex and promote 
DSB formation. The cytostatics induce DSB at sites concerning hematopoetic transcription 
factors such as MLL, AML1/CBFB, RARA and additionally decrease rejoining of generated 
DSB. HR and NHEJ proper function is therefore crucial for restoring genome integrity. 
Otherwise, accumulating mutations lead to malignant transformation, thus patients with 
impaired DNA repair may be predisposed to chemotherapy induced leukemia (Guillem, 
Tormo 2008).  
The other type of secondary leukemia is concerned with the previous use of alkylating 
agents. AML is diagnosed usually 5-7 years after chemotherapy and often follows MDS 
phase. Cytogenetic events common in this type of secondary leukemia are total or partial 
deletion of chromosome 5 and 7. Alkylating agents produce damage to the DNA forming 
monoadducts and diadducts. The process may result in interstrand and intrastrand cross 
links, producing single and double stand breaks. The damage caused by alkylating agents 
activates various DNA repair pathways. Monoadducts are usually repaired by NER and 
BER. Diadducts are managed by NER and HR. MMR by its influence on HR also takes part 
in repair processes induced in response to alkylator treatment. Cells with defective MMR 
function show an increased expression of RAD51, one of components of HR, and an 
increased microsatellite instability (Worillow, Allan et al. 2006). 
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3. HR defects in AML and MDS 
HR, together with NHEJ, is responsible for repair of DSB, the most important DNA lesion. 
DSB are produced naturally, especially during a normal programmed genom rearrangement 
and after the exposure to DNA toxic agents. HR requires homologous sequence to that of 
the broken end to start the repair process and in human cells deals mainly with DBS located 
within the replication forks. HR is more accurate than NHEJ.  
Impaired HR is a hallmark of Fanconi anemia (FA), a rare inherited disorder. Different 13 
FA proteins work together in HR DNA repair pathway and a defect of 1 of those proteins 
results in similar clinical phenotype: short stature, skeletal defects, bone marrow failure and 
hypersensitivity to DNA damaging agents such as mitomycin C. The patients are at high 
risk of developing AML and solid tumors, mainly gynecological. Diagnostic test for FA is 
based on detection of defective DNA repair: examination of chromosome breakage after 
exposure to mitomycin C or diepoxybutane. Chromosomal aberrations typical for FA 
patients with AML are also found in de novo AML, thus the knowledge based on this 
genetic disorder help us to understand the biology of AML. DNA repair defects typical for 
Fanconi anemia put those patients at high risk of AML and solid tumor development, 
especially breast, ovarian and pancreatic cancer. Defects in HR activity similar to those 
detected in AML patients with Fanconi anemia, were seen in AML secondary to previous 
anticancer treatment. Their occurrence in patients with de novo AML is rare.  
Single nucleotide G/C polymorphism in position 135 in gene encoding main protein active 
in HR pathway, RAD51, is correlated with AML predisposition (Seedhouse , Foulkner 2004). 
A polymorphism at codon 241 of another HR gene, XRCC3, results in Thr to Met 
substitution. Both polymorphisms were known previously to increase solid cancer 
susceptibility. The presence of both RAD51-135 C and XRCC3-241 Met protein variants 
increased the risk of secondary and primary AML development, 8 and 4 fold respectively.  
Observations made in patients with solid tumors with defective HR suggest increased 
sensitivity of cancer cells to cis-platin and to DNA repair inhibitors such as PARP or ATM 
inhibitors. So far such strategies are still at preclinical phase.  
4. NHEJ defects in AML and MDS 
NHEJ, together with HR, constitutes main pathways to repair DNA double strand breaks. 
NHEJ rejoins broken fragments with little requirement for homology and is extremely 
important in avoiding radiation toxicity. Translocation and mutations at the junction of the 
broken ends happen, that is why NHEJ is responsible for tumorigenic processes. Proper and 
balanced functions of NHEJ and HR are necessary to maintain genom integrity.  
Chromosomal instability in myeloid neoplasms results from deregulated NHEJ and 
inadequate DSB repair. The rate of NHEJ in leukemic blasts was 2-7 fold higher than in 
normal hematopoietic cells in vitro and resulted in increased misrepair , especially large 
deletions (Gaymes, Mufti et al. 2002). 
The number of double strand breaks is increased by the excessive reactive oxygen species 
(ROS) production. Certain genetic changes such as FMS - like tyrosine kinase 3 (FLT3) 
mutation in AML and RAS mutations in MDS are responsible for induction of ROS 
generation and lead to genomic instability. FLT3 mutations occur in half of the patients with 
AML. Activating mutation is seen in 30-35% of cases while internal tandem duplication ( 
FLT3 /ITD) in 20-25% of AML cases. The presence of FLT3/ITD carries extremely bad 
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prognosis in AML and is correlated with increased ROS generation and increased double 
strand brakes in DNA (Sallmyr, Fan et al. 2008). In FLT3/ITD-containing cells NHEJ is 
defective, which results in accumulating aberrant DNA structures (Seedhouse, Hunter et al. 
2006). Thus the cells depend on another DNA repair pathway. Upregulation of RAD51, the 
main component of HR pathway, was noted in patients with FLT3/ITD, defective in NHEJ, 
and could be partially responsible for resistance to chemotherapy (Seedhouse, Hunter et al 
2006). 
Increased ROS generation and accumulation of double strand brakes are seen also in 
patients with N- RAS mutation in MDS and AML. In addition to enhanced survival and 
proliferation of the cells, N-RAS mutation results in ineffective NHEJ leading to DNA 
instability (Rassool, Gaymes et al. 2007).  
5. BER in AML and MDS 
BER pathway is concerned with the removal of the base changed by alkylation, oxidation or 
ionizing radiation. BER also takes part in the single strand breaks repair. A defective base is 
detected and removed and the gap is filled by DNA polymerase, then the fragments are 
joined by XRCC1 /ligase III complex.  
Malfunction of BER pathway may contribute to cancer development. Data concerning 
polymorphism of XRCC1, one of the genes belonging to the BER pathway, in solid tumors 
are not conclusive, some studies show predisposition to the cancer in a wild type allele,  
the other do not. In AML studies, polymorphism of this gene (XRCC1 Arg399Gln) protects 
from development of the disease, especially of a secondary type. Patients with treatment 
related AML are more likely to have the wild –type of XRCC1 399Arg allele (Seedhouse, 
Bainton 2002).  
Important components of BER pathway are the poly(ADP-ribose) polymerases (PARP) 
family containing 18 members. Those proteins allow for access to DNA repair enzymes in 
the case of single strand DNA breaks. After recruitment of PARP proteins the strands are 
cut, repaired and rejoined. PARP1 is the best studied protein in the PARPs family. Inhibition 
of PARP1 results in conversion of single to double strand breaks increasing the need for HR 
repair. Cancer cells with defective HR processes switch to PARP mediated BER mechanisms. 
Hence, PARP1 inhibitors are extremely active in tumors deficient in HR pathway and thus 
converting DNA repair to BER. Such treatment could be alternative for selected AML 
patients with impaired HR (Gaymes, Shall 2009).  
6. NER in AML and MDS 
NER is able to eliminate a wide variety of DNA damage, for example, long adducts such as 
pyrimidine dimers or crosslinks caused by chemotherapy. It is responsible also for the 
elimination of DNA damage resulting from UV radiation and chemical substances. NER is 
necessary both in maintaining global genom integrity and in repair of actively transcribed 
genes. Long sequences of improper oligonucleotides can be excised in a multi-step process 
requiring helicases and nucleases followed by ligation of the repaired DNA fragments. 
Genes belonging to XP (xeroderma pigmentosum) group B and D encode helicases, enzymes 
responsible for unwinding DNA prior to transcription or NER. XPB protein is bound and 
modified by p210, the product of fusion gene bcr-abl responsible for chronic myeloid 
leukemia. Defective DNA helicases enhance genetic instability observed in this disorder.   
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The role of NER in AML pathogenesis and prognosis has also been investigated. Common 
polymorphisms in XPD gene belonging to NER pathway are associated with the risk of 
AML development and the outcome of the disease. XPD Lys 751 Gln variant is an 
independent prognostic marker for disease free survival and overall survival in elderly 
patients with AML (Allan, Smith 2004). Glutamine variant has altered enzymatic function 
with an impaired cellular response to genotoxins and is associated with the worse outcome 
as compared to lysine one. Heterozygotes had an intermediate AML outcome while 
homozygotes in the glutamine variant had the shortest overall and disease free survival. 
Homozygocity for the glutamine variant was also correlated with an increased risk of 
developing secondary AML after chemotherapy, but not after radiotherapy. Homozygocity 
did not affect de novo AML incidence. Moreover, the presence of the glutamine variant of 
XPD gene was associated with unfavorable cytogenetic profile in AML including patients 
with 5q and 7 q deletions (Smith, Worrillow et al. 2007). The same single nucleotide 
polymorphisms of XPD gene (XPD in Lys 751 Gln) together with the polymorphism of 
another gene in the same family (XPC Ala499 Val) were tested recently in AML patients 
with normal cytogenetics (Strom, Estey et al. 2010). Each polymorphism was an 
independent adverse prognostic factor for overall survival. Patients with the combination of 
variants in both genes had a significantly shorter overall survival (median 12 months) than 
carriers of wild type genes (median 44 months p=0.001).  
7. MMR in AML and MDS 
Processes of MMR play an important role in maintaining genome stability by detecting and 
repairing small insertions, deletions or misplaced bases which may occur during replication. 
Defects of MMR result in an increased rate of spontaneous mutations. Multiple replication 
errors occur in repetitive DNA sequences leading to microsatellite instability. Inadequate 
MMR may increase the risk of solid tumors and myeloid neoplasms (Ben-Yehuda, 
Krichevsky et al. 1996; Seedhouse, Das-Gupta et al. 2003). Microsatellite instability was 
observed in secondary leukemia and in elderly patients with AML (Das-Gupta, Seedhouse 
et al 2001), but not in de-novo young AML patients. The majority of patients showed 
multifocal changes. However, not all studies have found the increased microsatellite 
instability in AML patients (Rimsza et al 2000). MMR defects correlated with the presence of 
abnormalities of chromosome 5 and 7 (Ben-Yehuda, Krichevsky et al. 1996, Das-Gupta, 
Seedhouse et al. 2001). A high incidence of p53 mutations was also observed in this group of 
patients (Ben-Yehuda, Krichevsky at al. 1996). Improper p53 function may additionally 
enhance genom instability. 
8. Conclusions  
DNA repair defects are key events in multistep evolution of the neoplastic clone. The 
inherited improper function of DNA repair mechanisms may lead to accelerated genom 
instability, including tumor suppressor genes, resulting in neoplastic transformation. 
Increasing understanding of mechanisms leading to development and progression of 
myeloid malignancies may have future implications in the modern treatment. Leukemia is 
frequently specified by loss of a certain pathway, which may be the target of personalized 
treatment. So far the modification of DNA repair in AML and MDS is still at preclinical 
phase. Several potential problems with strategies influencing DNA repair arise. Most 
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important is the tendency for secondary malignancies because of genome instability and a 
high risk of rapidly increasing refractoriness. 
 
DNA repair 
mechanism 
Detected defect Correlation with AML Authors 
Homologous 
Repair 
Polymorphism in 
genes: RAD51, 
XRCC3, 
Increase risk of AML 
development 
Seedhouse, 
Foulkner 
2004 
Non Homologous 
End Joining 
Ineffective 
processes in 
patients with FLT3 
mutations 
Correlates with 
refractoriness of the 
disease 
Seedhouse, 
Hunter 
et al. 2006 
Base Excision 
Repair 
Polymorphism in 
gene XRCC1 
(Arg399Gln) 
Protects from AML 
development as 
compared with the wild 
type of allele 
Seedhouse, 
Bainton 2002 
Nucleotide 
Excision Repair 
Polymorphism in 
gene XPD 
(Lys751Gln) 
Adverse effect on overall 
survival and disease free 
survival in glutamine 
variant 
Allan, Smith 2004 
Mismatch Repair 
Microsatellite 
instability 
Increases risk of 
secondary leukemia; 
correlates with high risk 
cytogenetics 
Das-Gupta, 
Seedhouse 
et al. 2001 
Table 1. DNA repair defects in AML 
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